Biography:
Dr. D. Ezhilarasan is currently working as Professor in the Department of Pharmacology. He has completed M.Sc. with Gold Medal and earned his Ph.D. from University of Madras, Chennai, India and Université Catholque de Louvain, Brussels, Belgium through Erasmus Mundus Joint Doctoral Research Fellowship. He has obtained various Research Fellowships during his Ph.D. such as DST-INSPIRE, University Research fellowship from University of Madras and other prestigious awards.
Education:
Ph.D. Pharmacology and Toxicology, University of Madras, India / Université catholique de Louvain, Belgium
M.Sc. Environmental Science, Bharathiyar University, Coimbatore
M.Sc. Pharmacology and Toxicology, University of Madras, Chennai
B.Sc. Zoology, Presidency College, Chennai
Thrust Areas: Hepato-pharmacology; Chronic liver disease- ALD and NAFLD; Cancer biology; Cell signalling; stem cells; Wound Healing; Toxicology (toxicity tests) and Periodontology
Funded Project Details:
Alcoholic Liver Disease (2021-2024), ICMR, 35L.
Selected Recent Publications:
Gayatri Devi R, Ezhilarasan D*. Farnesol concurrent administration protects acetaminophen‐induced acute hepatic necrosis in mice. J Biochem Mol Toxicol. 2023. 10.1002/jbt.23478. IF. 3.6
Ezhilarasan D*, Shree Harini K. Nanodrug delivery: Strategies to circumvent nanoparticle trafficking by Kupffer cells in the liver. J Drug Deliv Sci Technol. 2023;86: 10473. IF. 5
Ezhilarasan D. Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms. Drug Metab Rev. 2023. doi: 10.1080/03602532.2023.2215478. IF. 7.2
Ezhilarasan D. Molecular mechanisms in thioacetamide-induced acute and chronic liver injury models. Environ Toxicol Pharmacol. Environ Toxicol Pharmacol. 2023;99:104093. IF. 5.78
Ezhilarasan D. Unraveling the pathophysiologic role of galectin-3 in chronically injured liver. J Cell Physiol. 2023;238(4):673-686. IF. 6.5
Shree Harini K, Ezhilarasan D*. Reply to “Wnt/beta-catenin signaling inhibitors and non-alcoholic fatty liver disease: Potential therapeutic implications”. Hepatobiliary Pancreat Dis Int. 2023;22(4):439-440. IF. 3.35
Shree Harini K, Ezhilarasan D*. Wnt/beta-catenin signaling and its modulators in nonalcoholic fatty liver diseases. Hepatobiliary Pancreat Dis Int. 2023. 22(4):333-345. IF. 3.35
Ezhilarasan D*, Najimi M. Deciphering the possible reciprocal loop between hepatic stellate cells and tumor cells in the tumor microenvironment of the liver. Crit Rev Oncol Hematol. 2023;182:103902. IF. 6.62
Ezhilarasan D*, Najimi M. Intercellular communication among liver cells in the perisinusoidal space of the injured liver: Pathophysiology and therapeutic directions. J Cell Physiol. 2023;238(1):70-81. IF. 6.5
Gheena S, Ezhilarasan D*. Personalized mRNA cancer vaccines with immune checkpoint inhibitors: A promising therapeutic approach in oral cancer patients. Oral Oncol. 2023;137:106282. IF. 5.97
Elumalai P, Ezhilarasan D*, Raghunandhakumar S. Letter to Editor on: "Ginger (Zingiber officinale roscoe) extract could upregulate the renal expression of NRF2 and TNFα and prevents ethanol-induced toxicity in rat kidney" by Akbari et al. Avicenna J Phytomed. 2023;13(1):1-2.
Rajkumar R, Ilango B, Vinothkumar K, Savidha R, Senthilkumar S, Ezhilarasan D, Sukumar E. Moringa oleifera seeds attenuate benzene-induced alterations in lipid peroxidation and antioxidant enzymes in liver and kidney tissues of Wistar rats. Indian Journal of Biochemistry & Biophysics 2023;60;26-30. IF.1.4
Ezhilarasan, D. and Lakshmi, T., 2022. A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. Oxidative Medicine and Cellular Longevity, 2022. IF: 6.54
Ezhilarasan, D., Lakshmi, T., Subha, M., Deepak Nallasamy, V. and Raghunandhakumar, S., 2022. The ambiguous role of sirtuins in head and neck squamous cell carcinoma. Oral Diseases, 28(3), pp.559-567. IF: 3.51
Elumalai, P., Ezhilarasan, D. and Lakshmi, T., 2022. Targeting head and neck cancer epigenetics with CRISPR-dCas9: An emerging therapeutic approach. Oral Oncology, 127, pp.105801-105801. IF: 5.33
Namrata, D., Lakshmi, T., Rushabh, D. and Ezhilarasan, D., 2022. Role of stress management in oral malignant and premalignant conditions. Oral Oncology, 127, pp.105813-105813. IF: 5.33
Ezhilarasan, D., Lakshmi, T. and Mallineni, S.K., 2022. Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges. Nanomedicine. IF: 5.31.
Ezhilarasan D. Hepatic stellate cells in the injured liver: Perspectives beyond hepatic fibrosis. Journal of Cellular Physiology. 2021. IF: 6.3.
Ezhilarasan D. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms. Toxicology. 2021. Toxicology. 2021;458:152840.IF. 4.7.
Rohit Singh T, Ezhilarasan D*. Lagerstroemia speciosa (L.) Pers., ethanolic leaves extract attenuates dapsone-induced liver inflammation in rats. Drug and Chemical Toxicology. 2021. IF. 3.35.
Ezhilarasan D*, Raghunandhakumar S. Boldine treatment protects acetaminophen-induced liver inflammation and acute hepatic necrosis in mice. J Biochem Mol Toxicol. 2021;35(4):e22697. IF. 3.642.
Ezhilarasan D. Relaxin in hepatic fibrosis: What is known and where to head? Biochimie. 2021, 187:144-151. IF. 4.1
Ezhilarasan D*, Lakshmi T, Subha M, Deepak Nallasamy V, Raghunandhakumar S. The ambiguous role of sirtuins in head and neck squamous cell carcinoma. Oral Dis. 2021 Feb 11. doi: 10.1111/odi.13798. IF. 3.72.
Ezhilarasan D. Advantages and Challenges in nanomedicines for chronic liver diseases: a hepatologist's perspectives. Eur J Pharmacol. 2021;893:173832. IF. 4.43.
Ezhilarasan D. Endothelin -1 in portal hypertension: The intricate role of hepatic stellate cells. Exp. Biol. Med. (Maywood). 2020;245(16):1504-1512. IF. 3.66.
Ezhilarasan D. Mitochondria: A critical hub for hepatic stellate cells activation during chronic liver diseases. Hepatobiliary Pancreat Dis Int. 2021;S1499-3872(21)00079-5.IF. 3.78.
Ezhilarasan D. Dapsone-induced hepatic complications: It’s time to think beyond methemoglobinemia.Drug Chem Toxicol.2021;44(3):330-333.IF. 3.35.